Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue
After investing six years in R&D, the firm is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client
Add BT as a preferred source
[SINGAPORE] Drug development typically takes six to 10 years just to identify a viable molecule, but Singapore biotech firm Nanyang Biologics reckons it can do the job in six minutes.
Originally founded as a biopharma startup to develop cancer and cardiovascular therapies, the company simultaneously spent six years building an artificial intelligence (AI) platform to accelerate its own drug discovery work.
Now it has commercialised that technology as NYB.AI, positioning it as a tool for pharmaceutical and health supplement manufacturers looking to slash costs and timelines.
TRENDING NOW
Asia-Pacific aviation: is up really the only way?
Russia’s ‘pivot to Asia’ takes a turn as it prioritises ties with isolated regimes over bigger economies
Why disciplined stewardship matters when managing wealth in uncertain markets
More than 15,000 sign up for national accounting body’s AI programme in two months
